Clinical Trial Detail

NCT ID NCT03564782
Title Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Istari Oncology, Inc.
Indications

Her2-receptor positive breast cancer

triple-receptor negative breast cancer

Therapies

PVSRIPO

Age Groups: adult senior

No variant requirements are available.